Profile data is unavailable for this security.
About the company
Context Therapeutics Inc. is a biopharmaceutical company advancing medicines for solid tumors. The Company is developing CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6-positive tumors, which is in preclinical development. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors, including ovarian, endometrial, testicular, and lung, and absent from or expressed at low levels in healthy adult tissues. CTIM-76 is capable of binding to tumor cells expressing CLDN6 and stimulating intra-tumoral T cells by the CD3 arm that is designed to be activated only upon tumor engagement while silent elsewhere. CTIM-76 has the potential for a wide therapeutic window, which is the difference between the dose required for the intended therapeutic effect and the dose required to elicit an unwanted side effect.
- Revenue in USD (TTM)0.00
- Net income in USD-21.32m
- Incorporated2015
- Employees5.00
- LocationContext Therapeutics Inc2001 Market Street, Suite 3915 Unit #15PHILADELPHIA 19103United StatesUSA
- Phone+1 (267) 225-7416
- Fax+1 (302) 655-5049
- Websitehttps://www.contexttherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Invivyd Inc | 0.00 | -206.82m | 131.25m | 94.00 | -- | 0.7347 | -- | -- | -1.86 | -1.86 | 0.00 | 1.50 | 0.00 | -- | -- | 0.00 | -73.08 | -- | -81.48 | -- | -- | -- | -- | -- | 5.77 | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
Syros Pharmaceuticals Inc | 6.98m | -144.49m | 133.64m | 68.00 | -- | 8.88 | -- | 19.14 | -5.01 | -5.01 | 0.2244 | 0.5633 | 0.0411 | -- | -- | 102,661.80 | -84.98 | -54.44 | -103.51 | -64.32 | -- | -- | -2,069.80 | -772.82 | -- | -- | 0.7332 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
ProQR Therapeutics NV | 14.49m | -28.84m | 133.90m | 157.00 | -- | 3.71 | -- | 9.24 | -0.3552 | -0.3552 | 0.1785 | 0.4441 | 0.0957 | -- | -- | 92,302.80 | -18.83 | -35.51 | -23.01 | -40.51 | -- | -- | -196.75 | -926.31 | -- | -- | 0.3557 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
Adlai Nortye Ltd (ADR) | 5.00m | -104.87m | 134.13m | 127.00 | -- | 1.69 | -- | 26.83 | -7.26 | -7.26 | 0.1931 | 2.15 | -- | -- | -- | 39,370.08 | -- | -- | -- | -- | -- | -- | -2,097.42 | -- | -- | -1.69 | 0.2843 | -- | -- | -- | -78.38 | -- | -- | -- |
Quantum-Si Inc | 1.29m | -91.82m | 135.02m | 159.00 | -- | 0.5321 | -- | 105.08 | -0.6482 | -0.6482 | 0.0091 | 1.79 | 0.004 | 0.196 | 7.93 | 8,081.76 | -28.67 | -- | -29.50 | -- | 49.26 | -- | -7,145.76 | -- | 30.03 | -- | 0.00 | -- | -- | -- | 27.55 | -- | -- | -- |
CytoDyn Inc | 0.00 | -51.69m | 135.45m | 12.00 | -- | -- | -- | -- | -0.055 | -0.055 | 0.00 | -0.1206 | 0.00 | -- | -- | 0.00 | -414.98 | -259.98 | -- | -- | -- | -- | -- | -235,303.80 | -- | -0.88 | -- | -- | -100.00 | -- | 62.14 | -- | -- | -- |
Fibrobiologics Inc | 0.00 | -22.53m | 135.46m | 10.00 | -- | -- | -- | -- | -1.03 | -1.03 | 0.00 | -0.1181 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -272.15 | -- | -- | -- |
Acumen Pharmaceuticals Inc | 0.00 | -55.94m | 136.38m | 51.00 | -- | 0.5205 | -- | -- | -1.05 | -1.05 | 0.00 | 4.36 | 0.00 | -- | -- | 0.00 | -22.89 | -- | -23.72 | -- | -- | -- | -- | -- | -- | -- | 0.1034 | -- | -- | -- | -22.20 | -- | -- | -- |
TriSalus Life Sciences Inc | 21.98m | -68.07m | 137.43m | 112.00 | -- | -- | -- | 6.25 | -2.09 | -2.09 | 0.7291 | -1.31 | 1.17 | 1.26 | 7.49 | 196,276.80 | -339.18 | -- | -11,196.50 | -- | 86.74 | -- | -291.08 | -- | 0.714 | -16.82 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
Repare Therapeutics Inc | 97.86m | -45.69m | 137.52m | 179.00 | -- | 0.5878 | -- | 1.41 | -1.10 | -1.10 | 2.30 | 5.51 | 0.3265 | -- | 9.22 | 546,698.30 | -15.25 | -23.40 | -18.73 | -26.37 | -- | -- | -46.69 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
Context Therapeutics Inc | 0.00 | -21.32m | 138.00m | 5.00 | -- | 3.48 | -- | -- | -1.34 | -1.34 | 0.00 | 0.5288 | 0.00 | -- | -- | 0.00 | -99.14 | -- | -114.72 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -61.53 | -- | -- | -- |
Galectin Therapeutics Inc | 0.00 | -44.78m | 141.70m | 14.00 | -- | -- | -- | -- | -0.7373 | -0.7373 | 0.00 | -1.14 | 0.00 | -- | -- | 0.00 | -177.94 | -92.08 | -373.85 | -121.97 | -- | -- | -- | -- | -- | -10.24 | 7.25 | -- | -- | -- | -15.26 | -- | -- | -- |
Adverum Biotechnologies Inc | 0.00 | -112.90m | 141.98m | 121.00 | -- | 0.7788 | -- | -- | -10.23 | -10.23 | 0.00 | 8.78 | 0.00 | -- | -- | 0.00 | -41.55 | -36.39 | -47.50 | -39.04 | -- | -- | -- | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
Caribou Biosciences Inc | 33.40m | -115.26m | 144.51m | 158.00 | -- | 0.4209 | -- | 4.33 | -1.45 | -1.45 | 0.4136 | 3.80 | 0.0886 | -- | 11.68 | 211,417.70 | -30.56 | -- | -33.02 | -- | -- | -- | -345.05 | -- | -- | -- | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Avidity Partners Management LPas of 02 May 2024 | 7.78m | 10.37% |
Deep Track Capital LPas of 02 May 2024 | 7.42m | 9.89% |
Great Point Partners LLCas of 31 May 2024 | 7.42m | 9.89% |
Opaleye Management, Inc.as of 31 Mar 2024 | 1.11m | 1.48% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 598.30k | 0.80% |
Affinity Asset Advisors LLCas of 31 Mar 2024 | 328.82k | 0.44% |
UBS O'Connor LLCas of 31 Mar 2024 | 296.68k | 0.40% |
swisspartners AGas of 30 Jun 2023 | 260.00k | 0.35% |
Adar1 Capital Management LLCas of 31 Mar 2024 | 205.93k | 0.28% |
HighTower Advisors LLCas of 31 Mar 2024 | 125.85k | 0.17% |